Amphastar on Tuesday received a complete response letter from the agency, which identified issues with a study assessing how humans interact with the device and device evaluation, among other concerns.
The drugmaker, which currently sells naloxone in pre-filled syringes, must address these issues with the nasal spray before resubmitting an application for FDA approval.
More articles on opioids:
Ohio couple criminally charged after 8-year-old son’s apparent heroin overdose
Nearly 70% of opioids not safely stored in households with children
Could medical marijuana help remedy the opioid epidemic?
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
